Newron Pharmaceuticals SPA

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Newron Pharmaceuticals SPA sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 6 completed early-phase tilt top decile by trial count

Newron Pharmaceuticals SPA: 9 sponsored US clinical trials, 1 recruiting.

Newron Pharmaceuticals SPA sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 6 completed. 3 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Treatment-resistant Schizophrenia, with 1 trials.

Top-decile sponsor footprint

Newron Pharmaceuticals SPA ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

NCT07184619
COMPLETED Phase 2

Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia

NCT04461119
TERMINATED Phase 2

Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

NCT02790034
COMPLETED Phase 2

A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

NCT02624167
COMPLETED Phase 1

A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.

NCT01955564
TERMINATED Phase 2

A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

NCT01264861
COMPLETED Phase 2

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

NCT01211587
COMPLETED Phase 3

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa

NCT00627640
COMPLETED Phase 3

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

NCT00605683

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 5
Phase 3 3

Therapeutic Areas

Treatment-resistant Schizophrenia 1
Idiopathic Parkinson´s Disease 1

What is open in the Newron Pharmaceuticals SPA pipeline

1 recruiting of 9 indexed (11% open); 6 completed (67%).

Phase mix: 3 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Treatment-resistant Schizophrenia (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Newron Pharmaceuticals SPA: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Newron Pharmaceuticals SPA sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share Newron Pharmaceuticals SPA4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAmylyx Pharmaceuticals
Newron Pharmaceuticals SPA sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Newron Pharmaceuticals SPA sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Newron Pharmaceuticals SPA page

9 registered trials is a research-attention snapshot, not an endorsement of Newron Pharmaceuticals SPA or any single study.

  • 1 of Newron Pharmaceuticals SPA's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Treatment-resistant Schizophrenia is the condition Newron Pharmaceuticals SPA studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Treatment-resistant Schizophrenia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Newron Pharmaceuticals SPA pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.